NDA 021540 describes CADUET, which is a drug marketed by Pfizer and is included in one NDA. It is available from five suppliers. There are four patents protecting this drug and three Paragraph IV challenges. Additional details are available on the CADUET profile page.
The generic ingredient in CADUET is amlodipine besylate; atorvastatin calcium. There are fourty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the amlodipine besylate; atorvastatin calcium profile page.
|Active Rx/OTC/Discontinued:||RX||Dosage:||TABLET;ORAL||Strength||EQ 5MG BASE;EQ 10MG BASE|
|Approval Date:||Jan 30, 2004||TE:||AB||RLD:||No|
|Patent:||5,686,104*PED||Patent Expiration:||May 11, 2015||Product Flag?||Substance Flag?||Delist Request?||Y|
|Patent:||5,969,156*PED||Patent Expiration:||Jan 8, 2017||Product Flag?||Substance Flag?||Delist Request?||Y|
|Patent:||6,126,971*PED||Patent Expiration:||Jul 19, 2013||Product Flag?||Substance Flag?||Delist Request?|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.